Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

Mok, TSK; Lopes, G; Cho, BC; Kowalski, DM; Kasahara, K; Wu, YL; de Castro, G; Turna, HZ; Cristescu, R; Aurora-Garg, D; Loboda, A; Lunceford, J; Kobie, J; Ayers, M; Pietanza, MC; Piperdi, B; Herbst, RS

Mok, TSK (通讯作者)，Chinese Univ Hong Kong, State Key Lab Translat Oncol, Shatin, Hong Kong, Peoples R China.

ANNALS OF ONCOLOGY, 2023; 34 (4): 377

Abstract

Background: We evaluated whether tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations have clinical utility as biomarkers for pe......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索